王茜
职位：科研助理| Email：wang_qian@fudan.edu.cn
教育背景
2001年-2005年 苏州大学 生物技术专业 本科
2006年-2008年 韩国庆尚大学 环境微生物专业 硕士
2015年-至今 复旦大学 病原生物专业 博士
工作经历
2008年-2009年 清华大学环境科学与工程系 科研助理
2009年-2011年 中科院上海巴斯德研究所 科研秘书
2011年-至今 复旦大学基础医学院病原生物系 助理研究员
工作期间发表论文
2018年
1. Xia, S.#, Xu, W.#, Wang, Q., Wang, C., Hua, C., Li, W., Lu, L., Jiang, S.* Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. International Journal of Molecular Sciences. 2018 19(2), 487.
2. Xu, W., Xia, S, Pu, J, Wang, Q., Li, P., Lu, L*, Jiang, S*. The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. Frontiers in Microbiology. 2018, 9:2643. doi: 10.3389/fmicb.2018.02643
3. Yang W, Sun Z, Hua C, Wang Q, Xu W, Deng Q, Pan Y, Lu L*, Jiang S*. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. Microbes and Infection. 2018 Oct - Nov;20(9-10):626-634.
2017年
1. Wang Q#, Dai Y#, Sun Z, Su X, Yu Y, Hua C, Xu W, Jiang S*, Lu L*. (2017). HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen. Emer. Microb. Infect. 6(11):e102.IF=5.605.
2. Qi, Q.#, Wang, Q.#, Chen, W., Du, L., Dimitrov, D.S., Lu, L.*, Jiang, S.* (2017). HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. Emer. Microb. Infect. 6(6):e59. IF=5.605.
3. Su, S. #, Wang, Q. #, Xu, W., Yu, F., Hua, C., Zhu, Y., Jiang, S.*, Lu, L.* (2017). A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity. AIDS. 31(7):885-894. IF=5.003.
4. Yu, Y., Deng, Y.Q., Zou, P., Wang, Q., Dai, Y., Yu, F., Du, L., Zhang, N.N., Tian, M., Hao, J.N., Meng, Y, Woo, J.F.W., Yuen, K.Y., Qin, C.F.*, Jiang, S.*, Lu, L.* (2017). A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. Nat. Commun. 8, 15672. IF=12.124.
5. Tan, Y., Wang, J., Su, S., Wang, Q., Jiang, S., Lu, L.*, Chen, Y.H.* (2017). Enhancement of endocytic uptake of HIV-1 virions into CD4-negative epithelial cells by HIV-1 gp41 via its interaction with POB1. Cell. Mol. Immunol. 14(6):568-571. IF=5.897.
6. Su, S., Zhu, Y., Ye, S., Qi, Q., Xia, S., Ma, Z., Yu, F., Wang, Q., Zhang, R., Jiang, S.*, Lu, L.* (2017). Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. J. Virol. 91(1): e01445-16. IF=4.663.
7. Li, H., Yu, F., Xia, S., Yu, Y., Wang, Q., Lv, M., Wang, Y., Jiang, S.*, Lu, L.* (2017). Chemically modified human serum albumin exhibits potent inhibitory activity against Ebola virus infection. Antimicrob. Agents Chemother. 61(4): e02168-16. IF=4.302.
8. Qi, Q., Wang, Q., Chen, W., Yu, F., Du, L., Dimitrov, D.S., Lu, L.*, Jiang, S.* (2017). Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. J. Infect. 75(1):68-71. IF=4.201.
9. Xu, W., Li, H., Wang, Q., Hua, C., Zhang, H., Li, W., Jiang, S.*, Lu, L.*, (2017). Advancements in developing strategies for sterilizing and functional HIV cures. Biomed. Res. Int. 2017:6096134. IF=2.476.
10. Xu, W., Dai, Y., Hua, C., Wang, Q., Zou, P., Deng, Q., Jiang, S.*, Lu, L.*. (2017). Genomic signature analysis of the recently emerged highly pathogenic A(H5N8) avian influenza virus: implying an evolutionary trend for bird-to-human transmission. Microb. Infect. 2017 Dec;19(12):597-604. IF=2.125.
11. 代嫣嫣，夏帅，王茜，陆路，姜世勃* (2016). 人类高致病性冠状病毒SARS-CoV 和MERS-CoV 的流行与突变 -- 共性与个性特征的启示. 生命科学, 28(3):357-366.
2016年
1. Sun, Z.#, Zhu, Y#., Wang, Q#., Ye, L., Dai, Y., Su, S., Yu, F., Ying, T., Yang, C., Jiang, S*, Lu, L*. An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. Emerg. Microb. Infect.2016. 5(6):e65 IF=4.012 (Nature系列杂志，#同等贡献)
2. Lai, W.#, Wang, C.#, Yu, F.#, Lu, L., Wang, Q., Jiang, X., Xu, X., Zhang, T., Wu, S., Zhang, Z., Dong, F., Cai, L., Jiang, S.*, Liu, K.* (2016). An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. Chem. Sci. 7, 2145-2150. IF=9.211.
3. Zhu, Y. #, Su, S#., Qi, L#., Wang, Q., Shi, L., Ma, Z., Jiang, S., Lu, L.*, Ye, S. *, Zhang, R. *. Rational improvement of gp41- targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations.Scientific Reports.2016 Sep 26;6:31983. IF=5.228.
4. Zhu, X. #, Zhu, Y. #, Ye, S. #, Wang, Q., Wu, W., Su, S., Sun, Z., Yu, F., Liu, Q., Wang, C., Zhang, T., Zhang, Z., Zhang, X., Xu, J., Du, L., Liu, K., Lu, L.*, Zhang, R. *, Jiang, S.*. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. Scientific Reports. 2015, 5:13028. IF=5.228 (投稿当年IF=5.578)
5. Li, W., Yu, F., Wang, Q., Qi, Q.Q., Su, S., Xie, L., Lu, L.*, Jiang, S.*. Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy. AIDS. 2016 Mar 27;30(6):827-38. IF=4.407 (投稿当年IF=5.554).
6. He, B., Fu, Y., Xia, S., Yu, F., Wang, Q., Lu, L.*, Jiang, S.* (2016). Intranasal application of polyethyleneimine suppressed influenza virus infection in mice. Emerg. Microbes Infect. 5, e41. IF=4.012
7. He, B., Xia, S., Yu, F., Fu, Y., Li, W., Wang, Q., Lu, L.*, Jiang, S.* (2016). The putative suppressing effect of IgG Fc-conjugated hemagglutinin (HA) stalk of influenza virus H7N9 on the neutralizing immunogenicity of Fc-conjugated HA head: implication for rational design of HA-based influenza vaccines. J. Gen. Virol. 97(2):327-33. IF=3.183.
8. Guo, X., Qiu, L., Wang, Y., Wang, Y., Wang, Q., Song, L., Li, Y., Huang, K., Du, X., Fan, W., Jiang, S., Wang, Q., Li, H., Yang, Y., Meng, Y., Zhu, Y.*, Lu, L.*, Jiang, S.* (2016). A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection. Microbes Infect. 18(2):148-52. IF=2.861.
2015年
1. Wang, Q., Bi, W., Zhu, X., Li, H., Qi, Q., Yu, F., Lu, L.*, Jiang, S.*. (2015). Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy. J. Virol. 2015 Jul 1; 89(13):6960-4. IF=4.648.
2. Zhu, X.#, Zhu, Y.#, Ye, S.#, Wang, Q., Xu, W., Su, S., Sun, Z., Yu, F., Liu, Q., Zhang, X., Xu, J., Du, L., Liu, K., Lu, L.*, Zhang, R.*, Jiang, S.* (2015). Improved pharmacological and structural properties of HIV fusion inhibitor AP3 over enfuvirtide: highlighting advantages of artificial peptide strategy. Sci. Rep. 5:13028. IF=5.578.
3. Liu, Q., Xia, S., Sun, Z., Wang, Q., Du, L., Lu, L.*, Jiang, S.* (2015). Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob. Agents Chemother. 2015 Jan; 59(1):742-4. IF=4.451.
4. Li, W., Wang, Q., Li, Y., Yu, F., Liu Q., Qin, B., Xie, L., Lu, L.*, Jiang, S.* (2015). A nanoparticle-encapsulated non-nucleoside reverse-transcriptase inhibitor with enhanced anti-HIV-1 activity and prolonged circulation time in plasma. Curr. Pharm. Design. 21(7):925-35. IF=3.288
5. Sun, Z, Wang, Q., Jia, R., Xia, S., Li, Y., Liu, Q., Xu, W., Xu, J., Du, L., Lu, L*., Jiang, S*. (2015). Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection. Viruses. 16; 7(2):798-819. IF=3.279
6. He, B., Zheng, B.J., Wang, Q., Du, L., Jiang, S.*, Lu, L.* (2015). Adenovirus-based vaccines against avian-origin H5N1 influenza viruses. Microbes Infect. 17(2):135-41. IF=2.731
7. Liu, H., Bi, W., Wang, Q., Lu. L., Jiang, S.* (2015). Receptor-binding domain-based HIV vaccines. Biomed. Res. Int. 2015:594109. IF=1.579
8. Xia, S., Wang, Q., Liu, S., Lu, L., Jiang, S.* (2015). Development of peptidic MERS-CoV entry inhibitors. Yao Xue Xue Bao. 2015 Dec; 50(12):1513-9.
2014年
1. Lu, L., Liu, Q., Zhu, Y., Chan, K.H., Qin, L., Li, Y., Wang, Q., Chan, J., Du, L., Yu, F., Ma, C., Ye, S., Yuen, K.Y., Zhang, R., Jiang, S.* (2014). Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 5:3067. IF=10.742.
2. Wang, C., Shi, W., Cai, L., Lu, L., Yu, F., Wang, Q., Jiang, X., Xu, X., Wang, K., Xu, L., Jiang, S.*, Liu, K.* (2014). Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains. J. Antimicrob. Chemother. 69(6):1537-45. IF=5.439.
3. Xu, W.†, Wang, Q.†, Yu, F., Lu, L.*, Jiang, S.* (2014). Synergistic Effect Resulting From Combinations of a Bifunctional HIV-1 Antagonist With Antiretroviral Drugs. J.Acquir.Immune Defic. Syndr.(JAIDS), 67(1):1-6. IF=4.394.
4. Xia, S., Liu, Q., Wang, Q., Sun, Z., Su, S., Du, L., Ying, T, Lu, L.*, Jiang, S.* (2014). Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res.2014 Dec 19;194:200-10. IF=2.827
2013年
1. Wang, C., Shi, WG., Cai, LF., Lu, L., Wang, Q., Zhang, TH., Li, JL ., Zhang, ZQ., Wang, K., Xu, L., Jiang, XF., Jiang, SB.*, Liu, KL.* (2013). Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule-Peptide Conjugates as New HIV-1 Fusion Inhibitors. J. Med. Chem. 56(6):2527-39. IF=5.480
2. Tong, P., Lu, F., Chen, X., Wang, Q., Yu, F., Zou, P., Yu, X., Li, Y., Lu, L., Chen, Y.H., Jiang, S*. (2013). An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. J. Antimicrob. Chemother. 68(11):2533-44. IF=5.439
3. Chao, LJ., Lu, L., Yang, HW., Zhu, Y., Li, Y., Wang, Q., Yu, XW., Jiang, SB.*, Chen, YH.* (2013). Identification of a Human Protein-Derived HIV-1 Fusion Inhibitor Targeting the gp41 Fusion Core Structure. PloS ONE. 8(5):e66156. IF=3.534
专利
1. 姜世勃，陆路，孙志武，王茜，杨霞。预防和控制人呼吸道合胞病毒感染的生物制剂及制备方法。中国专利申请号：201410561005.1； 申请日：2014.10.21。（已转让）
2. 姜世勃，陆路，孙志武，王茜。一种基于对称构象免疫原的艾滋病疫苗及其制备方法。中国专利申请号：201410734809.7；申请日：2014.12.4.
3. 姜世勃，陆路，王茜,毕稳稳。一种艾滋病治疗性疫苗组合物及其应用。中国专利申请号：201510169136.x；申请日：2015.4.13。
4. 姜世勃、陆路、李浩洋、于飞、王茜、杨霞。生物制剂及在制备预防和控制埃博拉病毒的药物中的应用。中国专利申请号：201510393377.2；申请日：2015.07.08。
5. 姜世勃；陆路；董铭心；戴秋云；王茜；于飞；杨霞；兰小宾；何振瑞；王志强。抗HIV病毒的马来酸B07凝胶制剂配方及制备方法。中国专利申请号：CN201510404482.1. 申请日：2015.10.28.
6. 姜世勃、陆路、毕稳稳，王茜。一种长效HIV融合抑制剂及其应用。中国专利申请号：201610051200.9；申请日：2016.01.26
7. 姜世勃、陆路、夏帅，王茜，于飞。广谱地抑制人类冠状病毒感染的多肽及其应用。中国专利申请号：201610070216.4；申请日：2016.01.30
8. 姜世勃，陆路，王茜，代嫣嫣, 孙志武。一种基于构象诱导加特异性表位选择加强免疫策略的新型HIV疫苗及其制备方法. 申请日：2016.09.01.
9. 姜世勃、陆路、王茜，代嫣嫣。HIV疫苗及其制备方法。中国专利申请号：201710431893.9；申请日：2017.06.09
10. 姜世勃，陆路，孙志武，王茜，杨霞。预防和控制人呼吸道合胞病毒感染的生物制剂及制备方法。中国专利申请号：201410561005.1； 申请日：2014.10.21。授权专利号：ZL201410561005.1； 授权日期：2017.10.24
11. 姜世勃，陆路，董铭心，戴秋云，王茜，于飞，杨霞，兰小宾，何振瑞，王志强。抗HIV病毒的马来酸B07凝胶制剂配方及制备方法。中国专利申请号：201510404482.1；申请日：2015.07.13。授权专利号：ZL201510404482.1； 授权日期：2017.10.20
12. 姜世勃，陆路，朱赟，王茜，杨霞，兰小宾，何振瑞。抗HIV病毒的JB蛋白直肠凝胶制剂配方及制备方法。中国专利申请号：201510360657.3；申请日：2015.06.26。授权专利号：ZL201510360657.3； 授权日期：2017.10.20
13. 陆路，姜世勃，王茜，苏珊，杨霞。多肽、其制备方法及抑制艾滋病病毒的用途。中国专利申请号：201811472964.0；申请日：2018.12.05。
14. 陆路，姜世勃，徐巍，刘腾，王茜，花晨，王聪，付玉红，李佩玉。马来酸卡比沙明在制备抗流感病毒药物中的应用。中国专利申请号：201810996687.7；申请日：2018.08.29。
15. 杨霞，姜世勃，陆路，徐巍，王茜，花晨。广谱抗微生物制剂、其制备方法及应用。中国专利申请号：201810691093.5；申请日：2018.06.28。
